Subject:
- Active Substance: Dulaglutide
- Name: Trulicity®
- Therapeutic area: Type 2 diabetes mellitus
- Pharmaceutical company: Lilly Deutschland GmbH
Time table:
- Start: 01.04.2023
- Final decision by G-BA: 21.09.2023
Final decision:
- No additional benefit proved